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Abstract 
Background: Malaria remains a global health problem and accurate surveillance of Plasmodium parasites that are 
responsible for this disease is required to guide the most effective distribution of control measures. Serological sur‑
veillance will be particularly important in areas of low or periodic transmission because patient antibody responses 
can provide a measure of historical exposure. While methods for detecting host antibody responses to Plasmodium 
falciparum and Plasmodium vivax are well established, development of serological assays for Plasmodium knowlesi, 
Plasmodium ovale and Plasmodium malariae have been inhibited by a lack of immunodiagnostic candidates due to 
the limited availability of genomic information.
Methods: Using the recently completed genome sequences from P. malariae, P. ovale and P. knowlesi, a set of 33 
candidate cell surface and secreted blood‑stage antigens was selected and expressed in a recombinant form using 
a mammalian expression system. These proteins were added to an existing panel of antigens from P. falciparum and 
P. vivax and the immunoreactivity of IgG, IgM and IgA immunoglobulins from individuals diagnosed with infections 
to each of the five different Plasmodium species was evaluated by ELISA. Logistic regression modelling was used to 
quantify the ability of the responses to determine prior exposure to the different Plasmodium species.
Results: Using sera from European travellers with diagnosed Plasmodium infections, antigens showing species‑
specific immunoreactivity were identified to select a panel of 22 proteins from five Plasmodium species for serologi‑
cal profiling. The immunoreactivity to the antigens in the panel of sera taken from travellers and individuals living in 
malaria‑endemic regions with diagnosed infections showed moderate power to predict infections by each species, 
including P. ovale, P. malariae and P. knowlesi. Using a larger set of patient samples and logistic regression modelling it 
was shown that exposure to P. knowlesi could be accurately detected (AUC = 91%) using an antigen panel consisting 
of the P. knowlesi orthologues of MSP10, P12 and P38.
Conclusions: Using the recent availability of genome sequences to all human‑infective Plasmodium spp. parasites 
and a method of expressing Plasmodium proteins in a secreted functional form, an antigen panel has been compiled 
that will be useful to determine exposure to these parasites.
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Background
Malaria is an infectious disease that remains a global 
health problem causing an estimated 219 million clinical 
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is caused by parasites of the genus Plasmodium and sev-
eral species are known to regularly infect humans. The 
vast majority of deaths occur in sub-Saharan Africa and 
are caused by Plasmodium falciparum, whereas outside 
of Africa, Plasmodium vivax is responsible for over half 
of all malaria infections leading to significant morbidity 
and mortality [2]. Much less is known about the other 
human-infective Plasmodium species, Plasmodium 
malariae, Plasmodium ovale and Plasmodium knowlesi 
both in terms of their global distribution and clinical 
impact. Plasmodium knowlesi, a parasite typically found 
in macaques, is a significant cause of human malaria in 
Southeast Asia, causing a spectrum of disease ranging 
from mild to fatal infections [3]. Malaysia has the high-
est incidence of P. knowlesi malaria with over 6700 cases 
reported in the last 2 years compared to only 85 cases of 
indigenous human malaria (unpublished data from the 
Ministry of Health, Malaysia).
Diagnosis of Plasmodium infections and epidemio-
logical surveillance is important for guiding the dis-
tribution of resources into intervention measures and 
establishing their clinical impact over time [4]. Methods 
to measure the prevalence of Plasmodium infections 
include microscopy, rapid diagnostic tests (RDTs) and 
PCR-based approaches, each differing in their sensitiv-
ity, infrastructure requirements, and ability to diagnose 
the different species. Serological assays can provide a his-
torical record of infection and because of the specificity 
of antibody-antigen binding, could also potentially dis-
criminate between different Plasmodium spp. infections. 
Host antibodies appear rapidly after initial infection and 
can persist for months and even years after the parasites 
have been cleared [5, 6]. Serological screening has been 
applied in epidemiological settings to detect parasite 
exposure, evaluate transmission trends of malaria [7–10], 
and identify antibody-based correlates of protection [11, 
12]. It is also used in blood donation centres, where, due 
to the increase in international travel and migration, the 
need for serological diagnosis is becoming more impor-
tant to reduce the risk of transfusion-transmitted infec-
tions. Currently, many centres assess these risks using 
patient questionnaires which is generally unsatisfactory; 
moreover, the limitations and costs of the currently avail-
able serological tests often make implementing these 
assays economically unattractive [13].
Many antibodies recognise epitopes that are only 
formed in the context of an antigen in its native con-
formation [14]. To detect these antibodies, it is vitally 
important that the proteins used are correctly folded 
so that they faithfully form these epitopes. Expressing 
Plasmodium proteins in a soluble recombinant form has 
proved challenging, perhaps because of the high A:T 
content of the genome and lack of recognisable protein 
domains in many Plasmodium proteins [15]. This prob-
lem is especially acute for parasite proteins that are 
secreted or embedded in membranes because these 
proteins additionally contain structurally critical post-
translational modifications, such as disulfide bonds that 
are not typically added by many commonly used expres-
sion systems. Recently, a method of expressing large 
panels of recombinant Plasmodium proteins was devel-
oped that retained many of their biochemical functions 
[16]. Central to this approach was the use of a mamma-
lian expression system which increases the chances that 
appropriate post-translational modifications are correctly 
added to ensure proteins adopt their native fold. For anti-
gens expressed using this method a large fraction—and 
in some cases all—the immunoreactivity to antigens was 
heat-labile, demonstrating that antibodies that recognise 
conformational epitopes represent a major component of 
the humoral response [16]. Previously, this approach was 
used to create libraries of soluble recombinant merozo-
ite cell surface and secreted proteins that encompass the 
entire ectodomain from both P. falciparum [16, 17] and 
P. vivax [18]. Using sera from patients living in endemic 
regions, several of these proteins were found to be highly 
immunoreactive and might therefore be useful target 
antigens in serological assays [8, 12]. Expanding the anti-
gen panel to include the other parasite species infecting 
humans would be especially valuable if they could be 
used to determine exposure to the different species of 
Plasmodium. Here, the recent availability of high-quality 
genome sequences from the three other human-infective 
Plasmodium parasites: P. knowlesi, P. ovale and P. malar-
iae were used to extend the available panel of proteins 
and were tested for reactivity to sera from individuals 
infected with different Plasmodium parasites.
Methods
Study populations
Collection of sera from Malawian adults that were  pre-
viously used to determine its effectiveness as an adjunct 
therapy to treat cerebral malaria was approved by the 
National Health Sciences Research Committee of Malawi 
[19]. Plasma from adult travellers, microscopy-diagnosed 
with malaria and species further confirmed by multiplex 
PCR for all species except P. knowlesi [20] after return-
ing from visits to malaria-endemic regions were obtained 
from the Karolinska University Hospital, Stockholm, 
Sweden (n = 81). Of these, 53 were from travellers of 
European origin and 28 from travellers born in malaria-
endemic regions as follows: Angola (3 individuals), 
Burundi (1), Cameroon (1), Democratic Republic of the 
Congo (1), Eritrea (4), Ethiopia (1), The Gambia (1), India 
(3), Ivory Coast (2), Kenya (5), Pakistan (1), Thailand (1), 
and Uganda (4). Plasma from an endemic region with 
